Şirket yükleniyor
Just reported
Q3 2026 results
From West Pharmaceutical Services's results release of 29 Ekim 2026; its quarterly report has since been filed.
Revenue
Actual
$874,5M
+%8,7 y/y
+%0,3 q/qGuided
$827,5M
midpoint
Above guide+%5,7EPS, GAAP
Actual
$3,02
+%57 y/y
+%40 q/qGuided
—
No guide given
Operating income, GAAP
Actual
$267,4M
+%60 y/y
+%49 q/qGuided
—
No guide given
Company outlook
Full year 2026
- Revenue$3,41B – $3,42B+%11 y/y Raised +%1,6
- EPS, adjusted$9,38 – $9,48Raised +%5,4
Set against the company's own guidance and the same quarter a year earlier, not analysts' estimates, which we do not hold. Adjusted figures are the company's own non-GAAP measures, as stated in the release.
The full earnings report →Keep exploring
The themes West Pharmaceutical Services is part of, the highest-graded companies in its industry, and the companies in its sector whose grade rose recently.
Highest-graded in Medical Instruments and Supplies
Graded A or B and worth $2B or more: A first, then the largest.
ISRGIntuitive Surgical, Inc.$153,8BA+
MDLNMedline Inc.$51,9BA
ALCAlcon Inc.$36,1BA
BLCOBausch & Lomb Corp$7,5BA-
ATRCAtriCure, Inc.$2,9BA
Grade rose recently in Healthcare
Rose to A or B on a filing in the last 90 days, worth $2B or more: largest first.
DHRDanaher Corporation21 Eki 2026CBGraded C, now B
MCKMckesson Corporation4 Kas 2026BAGraded B, now A
CVSCVS Health Corp4 Kas 2026BAGraded B, now A
EWEdwards Lifesciences Corporation4 Kas 2026BAGraded B, now A
GEHCGE Healthcare Technologies Inc.28 Eki 2026CAGraded C, now A
West Pharmaceutical Services Inc. şirketinin ABD Menkul Kıymetler ve Borsa Komisyonu’na (SEC) sunduğu kendi belgelerinden kuruldu. Rakamlar bildirildiği gibidir; hisse başına geçmiş bugünkü hisse tabanına göre yeniden hesaplanmıştır. Bu bir işletmeyi anlatır — yatırım tavsiyesi değildir ve alma ya da satma önerisi değildir.
